What is the AVO treatment for Chronic Lymphocytic Leukemia (CLL)? Acalabrutinib, Venetoclax, Obinutuzumab for High-Risk Patients
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.